Crinetics Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Crinetics Pharmaceuticals has a total shareholder equity of $539.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $635.4M and $96.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$558.56m |
| Equity | US$539.11m |
| Total liabilities | US$96.25m |
| Total assets | US$635.35m |
Recent financial health updates
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Recent updates
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
Mar 21Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
Jan 27
Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares
Dec 06Financial Position Analysis
Short Term Liabilities: CRNX's short term assets ($574.2M) exceed its short term liabilities ($43.9M).
Long Term Liabilities: CRNX's short term assets ($574.2M) exceed its long term liabilities ($52.3M).
Debt to Equity History and Analysis
Debt Level: CRNX is debt free.
Reducing Debt: CRNX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CRNX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CRNX has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 36.3% each year.